e-ISSN: Pending
Negative / Null Result ReportBiochemistry, Genetics and Molecular Biology· cited by 44

Phase 1b open-label randomized study of the oncolytic adenovirus DNX-2401 administered with or without interferon gamma for recurrent glioblastoma.

Frederick F. Lang; Nam Tran; Vinay K. Puduvalli; J. Bradley Elder; Karen Fink; Charles A. Conrad; W. K. Alfred Yung; Marta Penas‐Prado · 2017 · Journal of Clinical Oncology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract (excerpt)

2002 Background: DNX-2401 is a replication-competent, tumor-selective, oncolytic adenovirus with enhanced infectivity that causes durable tumor control by killing tumor cells and eliciting antitumor immunity. To increase immune activation,…

Excerpt shown for reference under fair use — read the full paper at the publisher.

Read full paper at publisher

Hosted by the publisher — may require access.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1200/jco.2017.35.15_suppl.2002